Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05
Bradley C. Martin profile photo

Bradley C. Martin

High Impact

Professor

Also affiliated: Pennington Biomedical Research Center (2009); University of North Carolina at Chapel Hill (2020); University of Arizona (2021); University of Georgia (1992–2005); University of Utah (2013); Augusta University (2002); University of Arkansas Medical Center (2016–2026); University of Florida Health (2021); University of Mississippi Medical Center (2018); University of Florida (2021); University of Mississippi (2003); Health Services Research & Development (2014); Central Arkansas Veterans Healthcare System (2014–2018); G.V. (Sonny) Montgomery VA Medical Center (2018); Boehringer Ingelheim (United States) (2013); Center for Surveillance, Epidemiology, and Laboratory Services (2017)

Pharmacy Practice, College of Pharmacy

47 h-index 222 pubs 10,445 cited

  • Humans
  • Female
  • Male
  • Middle Aged
  • Adult
  • United States
  • Aged
  • Retrospective Studies
  • Analgesics, Opioid
  • Adolescent
  • Young Adult
  • Medicaid
  • Opioid-Related Disorders
  • Chronic Pain
  • Aged, 80 and over

Biography and Research Information

OverviewAI-generated summary

Bradley C. Martin is a Professor in the College of Pharmacy at the University of Arkansas for Medical Sciences, focusing on pharmacy practice. His research interests include the characteristics of initial prescription episodes and their correlation with long-term opioid use, particularly in the United States. He has investigated adherence measures using administrative claims data and explored the role of smartphone applications in improving medication adherence for patients and providers.

Dr. Martin has been involved in studies examining trends in opioid use for non-cancer pain conditions, as well as the risks associated with opioid abuse and dependence among individuals receiving chronic opioid therapy. His work also extends to systematic reviews and meta-analyses, such as investigating the role of RAS oncogenes in lung cancer survival. He is a highly cited researcher with an h-index of 50 and over 260 publications. He leads a research group and maintains an active lab website, collaborating with several colleagues at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 47
  • Publications: 222
  • Citations: 10,445

Positions

  • Professor 2004–present
    University of Arkansas for Medical Sciences Pharmacy Practice, College of Pharmacy Institutional directory

Selected Publications

  • RWD115 ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND INCIDENT ALCOHOL USE DISORDER AMONG PATIENTS WITH DIABETES: A REAL-WORLD EVIDENCE STUDY (2026)
    Value in Health DOI OpenAlex
  • Rural–Urban Differences in Use of Diabetes Self-Management Education and Support in Arkansas, 2015–2019 (2026)
  • Venous thromboembolism following oncologic pancreas and liver surgery (2025)
    HPB 2 citations DOI OpenAlex
  • Metformin use is associated with reduced systemic steroid courses among pediatric asthma patients with diabetes or elevated blood glucose levels (2025)
    Respiratory Medicine 1 citation DOI OpenAlex
  • Historic and contemporary selection define conservation units for a short-range endemic within an anthropogenically-altered riverscape (2025)
    Global Ecology and Conservation DOI OpenAlex
  • Venous thromboembolism diagnosis definition in claims data: implications for research (2025)
    Journal of Thrombosis and Thrombolysis 5 citations DOI OpenAlex
  • Disparities in Extended Venous Thromboembolism Prophylaxis After Pancreatic Cancer Surgery (2025)
    Annals of Surgical Oncology 3 citations DOI OpenAlex
  • Clinical outcomes of extended venous thromboembolism prophylaxis after oncologic colorectal surgery (2025)
    Journal of Gastrointestinal Surgery 1 citation DOI OpenAlex
  • GeoGenIE: a deep learning approach to predict geographic provenance of biodiversity samples from genomic SNPs (2024)
    Bioinformatics Advances 1 citation DOI OpenAlex
  • An updated view on the influence of initial opioid prescription characteristics on long-term opioid use among opioid naïve patients (2024)
    Drug and Alcohol Dependence 4 citations DOI OpenAlex
  • The role of prescribed controlled substance acquisition as potential triggers of opioid overdose: A case-crossover study (2024)
    International Journal of Drug Policy 1 citation DOI OpenAlex
  • A Statewide Examination of Medical Cannabis Purchasing Patterns in Arkansas Over the Three Years Immediately Following Legalization (2024)
    Cannabis and Cannabinoid Research 1 citation DOI OpenAlex
  • Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. (2024)
    PubMed 2 citations DOI OpenAlex
  • Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study (2024)
    Journal of Substance Use and Addiction Treatment 2 citations DOI OpenAlex
  • Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)
    Translational Lung Cancer Research 1 citation DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

  • Impact of Opioid Dosing Strategies on Pain Scores and Adverse or Unintended Clinical Outcomes NIH Co-Investigator
  • The influence of post-partum coverage extension on maternal depression screening NIH/Nat. Inst. of Child Health & Human Development via Tulane University Principal Investigator
  • Arkansas Consortium for Health Services Research NIH Principal Investigator
  • Prescribers, Pharmacists, and the Opioid Dilemma NIH/Nat. Inst. on Drug Abuse via RTI, International Co-Investigator
  • Use and Abuse of Prescription Opioids Among OEF/OIF Veterans NIH Co-Investigator
  • Early Care Decisions and the Risk of Long-Term Opioid Use in Patients with Low Back Pain UAMS Intramural Grant (CTSA) Principal Investigator
  • ADVANCING RISK ADJUSTMENT FOR SCHIZOPHRENIA NIH Principal Investigator
  • Utilization Patterns and Persistence of Antihormonal Therapies for Breast Cancer NOVARTIS Pharmaceuticals Corporation Principal Investigator

Collaboration Network

262 Collaborators 89 Institutions 8 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics